What is MGB Biopharma?
MGB Biopharma is a specialized biopharmaceutical enterprise dedicated to the discovery and development of a new class of anti-infective medicines. At the core of its innovation is the Minor Groove Binder (MGB) platform, which utilizes a unique mechanism of action to combat bacterial infections. The company's lead candidate, MGB-BP-3, represents a significant advancement in therapeutic efficacy, particularly for treating Clostridium difficile infections. By prioritizing high-impact research and development, MGB Biopharma aims to disrupt the traditional antibiotic market, offering superior alternatives to existing standards of care that are increasingly compromised by widespread resistance.
How much funding has MGB Biopharma raised?
MGB Biopharma has raised a total of $7.4M across 2 funding rounds:
Unspecified
$6.4M
Unspecified
$1M
Unspecified (2014): $6.4M with participation from TRI Cap
Unspecified (2017): $1M led by The TRICAPITAL Syndicate and Archangel Investors Ltd
Key Investors in MGB Biopharma
TRI Cap
Tweed Renaissance Investors Capital is a prominent business angel syndicate based in the Scottish Borders, focused on providing growth capital to high-potential enterprises.
Archangel Investors Ltd
A leading business angel syndicate known for supporting early-stage technology and life science companies with significant growth potential.
What's next for MGB Biopharma?
With the support of its latest capital raise, MGB Biopharma is poised to accelerate the clinical development of its lead assets. The strategic roadmap involves scaling manufacturing capabilities and expanding the scope of its clinical trials to demonstrate the broad-spectrum potential of its MGB compounds. As the firm moves toward potential commercialization, the focus will remain on securing regulatory approvals and establishing partnerships that can facilitate the global distribution of its life-saving therapies. The current funding environment suggests a robust outlook for the company as it continues to address one of the most pressing challenges in modern medicine: the rise of drug-resistant pathogens.
See full MGB Biopharma company page
